Fig. 5: rFGF1ΔHBS rescues ADR-induced nephropathy.
a Schematic diagram of the ADR-induced (10.5 mg/kg body weight) nephropathy (AN) model and chronic rFGF1ΔHBS treatment. b–i AN mice were treated with rFGF1ΔHBS (0.5 mg/kg body weight) or buffer control for 5 weeks; normal BALB/c mice served as additional controls (Ctrl). b–d ELISA analysis of blood urea nitrogen (BUN) levels (b), creatinine levels (c), and UACR (d) in each group. e H&E staining, Masson’s trichrome staining, PAS staining, immunohistochemistry staining with WT-1 antiserum, and EM images of renal tissues in each group. Scale bar, 50 μm for H&E, Masson’s trichrome, PAS, and WT-1 staining images; Scale bar, 0.5 μm for EM images. f–i Quantification of mesangial expansion (f), fibrosis area (g), WT-1-positive cells per glomerulus (h), and podocyte foot process effacement (i) in renal tissues. Data are presented as the mean ± SEM (n = 5); *p < 0.05, **p < 0.01, ***p < 0.001
